Shots:

• The P-III STELLAR-4 study involves assessing of Selonsertib (18mg- 6mg- qd) vs PBO (qd) in patients with compensated cirrhosis (F4) due to NASH for 240 wks.
• The P-III study didn’t meet its 1EPs @48wks.- achieved a ≥ 1-stage improvement in fibrosis (14.4%- 12.5% or 12.8%) and was well-tolerated with safe results
• Selonsertib is qd an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1)- evaluated in P-II ATLAS study in combination with cilofexor (GS-9674) and firsocostat (GS-0976) for advanced fibrosis due to NASH

Ref: Gilead | Image:Gilead